Arbutus Biopharma Corporation
Sağlık
COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.
$4.03
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
WebsiteAnalysis (Turkish): ABUS Hissesi Caiz mi, Helal mi? Arbutus Biopharma Corporation Katılım Analizi